Καταχωρήθηκε: Πέμπτη 23 Δεκ 2021
In the coronavirus disease 19 (COVID-19) pandemic era, the number of haploidentical hematopoietic cell transplantations (HCTs) with peripheral blood (PB) grafts increased significantly compared with HCTs with bone marrow (BM) grafts, which may be associated with adverse outcomes. We compared outcomes of HCT in BM graft and PB graft recipients age ≥18 years with hematologic malignancies who underwent T cell- replete haploidentical HCT and received graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil.

•The risk of steroid-refractory acute graft-versus-host disease (GVHD) was higher with peripheral blood (PB) grafts compared with bone marrow (BM) grafts for haploidentical hematopoietic cell transplantation (haplo-HCT).

•There was a greater risk of therapy-requiring chronic GVHD with PB grafts compared with BM grafts for haplo-HCT.

•There was a greater risk of infections with PB grafts versus BM grafts for haplo-HCT.

•The time to engraftment and duration of hospitalization were similar with BM grafts and PB grafts.

•Immune reconstitution was similar with BM grafts and PB grafts

Presenter: Prof Spyridonidis
Participants: Dr Liga, Dr Tsokanas

Σχετικά Αρχεία



Τηλέφωνα Επικοινωνίας:


Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)


βρείτε μας στο χάρτη


Login / Sitemap


© Copyright 2015 - 2022 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας